References
- Public Assessment Report Mutual Recognition Procedure ILUVIEN® 190 micrograms Intravitreal Implant in Applicator. Source: http://www.mhra.gov.uk/home/groups/par/documents/websiteresources/con171936.pdf. Accessed 21 September 2016.
- ILUVIEN Summary of Product Characteristics. Source: https://www.medicines.org.uk/emc/medicine/27636. Accessed 21 September 2016.
- Campochiaro PA, et al. Sustained delivery fluocinolone acetonide vitreous inserts provide benefit for at least 3 years in patients with diabetic macular edema. Ophthalmology. 2012;119:2125–2132. DOI:10.1016/j.ophtha.2012.04.030
- Chakravarthy U, Bailey C, Koch F Safety and clinical outcomes in the European registry study of ILUVIEN implant (fluocinolone acetonide; FAc) usage in diabetic macular edema. Presented in session ‘Free Paper Session 4: Vascular Diseases and Diabetic Retinopathy 2ʹ on Thursday 8 September 11am in Auditorium A2 at the The16th Congress of the European Retina, Macula and Vitreous Society.
- Brand C, Mitchell P, Parikh S, et al. Real-world outcomes at 1 year with ranibizumab 0.5 mg in DME patients with low baseline VA: results from the 3rd interim analysis of LUMINOUS study. Presented on Thursday 8th September 2016 at the16th Congress of the European Retina, Macula and Vitreous Society. Source: http://euretina.org/copenhagen2016/programme/free-papers-details.asp?id=4425&day=0
- NICE technology appraisal guidance [TA301]. Fluocinolone acetonide intravitreal implant for treating chronic diabetic macular oedema after an inadequate response to prior therapy. 27 November 2013. Source: https://www.nice.org.uk/guidance/ta301/chapter/1-Guidance.
- Kiss S, Liu Y, Brown J, et al. Clinical utilization of anti-vascular endothelial growth-factor agents and patient monitoring in retinal vein occlusion and diabetic macular edema. Clin Ophthalmol. 2014;26(8):1611–1621.
- Summary of product characteristics for ILUVIEN 190 micrograms intravitreal implant in applicator. Source: https://www.medicines.org.uk/emc/medicine/27636. Accessed 21 September 2016.
- Ch’ng S, Brent A, Banerjee S The economic impact of Intravitreal fluocinolone acetonide (Iluvien®) in refractory diabetic macular oedema in the National Health Service (NHS), United Kingdom. Presented at the European Society of Retina Specialists meeting in Copenhagen, Denmark between 8th and 11th September 2016. Source: http://euretina.org/copenhagen2016/programme/posters-details.asp?id=7555
- Sivaprasad S, Oyetunde S. Impact of injection therapy on retinal patients with diabetic macular edema or retinal vein occlusion. Clin Ophthalmol. 2016;10:939–946.